{"id":"NCT01645787","sponsor":"Columbia University","briefTitle":"Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients","officialTitle":"Columbia SMA Project: 4-AP as a Potential SMA Therapeutic Agent and Biological Mechanisms of Action","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-06-01","primaryCompletion":"2015-09","completion":"2015-09","firstPosted":"2012-07-20","resultsPosted":"2024-09-03","lastUpdate":"2024-09-03"},"enrollment":11,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Spinal Muscular Atrophy"],"interventions":[{"type":"DRUG","name":"4-aminopyridine","otherNames":["dalfampridine-ER","Ampyra"]},{"type":"DRUG","name":"Placebo","otherNames":["Sugar pill"]}],"arms":[{"label":"4-aminopyridine (Ampyra)","type":"ACTIVE_COMPARATOR"},{"label":"Sugar pill","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess whether 4-AP (Dalfampridine-ER, Ampyra) improves walking ability and endurance in adult patients with Spinal muscular atrophy (SMA) Type 3 compared to placebo and whether the duration of treatment affects outcome.","primaryOutcome":{"measure":"Six Minute Walk Test (6MWT) With Kinematic Evaluation of Gait (Short Term)","timeFrame":"Day 14 of each short-term intervention period","effectByArm":[{"arm":"Short Term 4-aminopyridine (Ampyra)","deltaMin":293.05,"sd":null},{"arm":"Short Term Placebo","deltaMin":299.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":11},"commonTop":["Fall","Dizziness","Headache/migraine","Upper Respiratory Infection (URI)","Insomnia"]}}